Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RSVpreF Vaccine in Pregnant Women with HIV and Their Infants
NCT06325657Phase 3Completed
- Sponsor
- Pfizer
- Start
- Mar 2024
- Primary completion
- Jun 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of RSVpreF vaccine in respiratory syncytial virus infection (RSV), sponsored by Pfizer. Started Mar 2024; status: completed.
02
Drugs
RSVpreF vaccine
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT06325657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06325657.